ACAD vs. MLTX, MOR, EVO, SMMT, IDYA, JANX, INDV, ARWR, CRNX, and XENE
Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Evotec (EVO), Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA), Janux Therapeutics (JANX), Indivior (INDV), Arrowhead Pharmaceuticals (ARWR), Crinetics Pharmaceuticals (CRNX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
ACADIA Pharmaceuticals received 826 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 76.27% of users gave MoonLake Immunotherapeutics an outperform vote while only 73.07% of users gave ACADIA Pharmaceuticals an outperform vote.
In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 6 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.50 beat ACADIA Pharmaceuticals' score of -0.17 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 27.5% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 15.3% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ACADIA Pharmaceuticals currently has a consensus target price of $32.13, suggesting a potential upside of 92.25%. MoonLake Immunotherapeutics has a consensus target price of $74.46, suggesting a potential upside of 75.24%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe ACADIA Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to ACADIA Pharmaceuticals' net margin of -8.44%. MoonLake Immunotherapeutics' return on equity of -9.22% beat ACADIA Pharmaceuticals' return on equity.
ACADIA Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ACADIA Pharmaceuticals beats MoonLake Immunotherapeutics on 10 of the 17 factors compared between the two stocks.
Get ACADIA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACADIA Pharmaceuticals Competitors List
Related Companies and Tools
